Abstract

DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR ANTI-TUBERCULAR DRUGS IN PHARMACEUTICAL DOSAGE FORM

Pooja. G. Sakharkar*, Anil P. Dewani, and Prof. Dr. Anil V. Chandewar

ABSTRACT

Anti-tubercular medication combinations in fixed doses are used to treat tuberculosis. For a patient to be cured without relapsing and to prevent the development of drug-resistant mutants, which may happen during therapy, a combination of treatments including several medications is required. The measurement of INH, PYZ, and RIF in fixed dose combination pills was devised and confirmed using an HPLC-diode array detector (DAD) approach. Chromatographic tests were run on a Waters 717plus HPLC system, and the separation was done on an analytical column called a Hypersil Gold C18 (250 4.6 mm id, 5 m). A mobile phase of (A) acetonitrile and (B) 10 mM monobasic sodium phosphate buffer with 0.2% triethylamine (96): Acetonitrile (4) at a flow rate of 1.5 mL/min was used to carry out gradient elution. The show lasted 30 minutes in total. Using a DAD, INH, PYZ, and RIF were found at 266 nm. The approach was demonstrated to be focused, linear (R2 > 0.999), and accurate (%RSD). Pharmaceutical formulation QC analyses can use an accurate, reliable method. editorial column.

Keywords: HPLC, Tuberculosis, DAD, INH, PYZ, RIF, Chromatography etc.